Handelsbanken Fonder Ab Pulmonx Corp Transaction History

Handelsbanken Fonder Ab

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	BUY	$4.92 - $17.35 $79,212 - $279,335	16,100 New	16,100 $136,000
Q2 2022 Aug 03, 2022	SELL	$14.0 - $27.95 $127,400 - $254,345	-9,100 Closed	0 $0
Q4 2021 Feb 08, 2022	SELL	$29.72 - $45.1 $148,600 - $225,500	-5,000 Reduced 35.46%	9,100 $292,000
Q3 2021 Nov 10, 2021	BUY	$35.98 - $44.48 $143,920 - $177,920	4,000 Added 39.6%	14,100 $507,000
Q2 2021 Aug 03, 2021	BUY	$37.61 - $48.0 $379,861 - $484,800	10,100 New	10,100 $446,000

123

31M

300

204K

Ticker LUNG
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 37,268,400
Market Cap $236M
Description
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a ...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.